-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626

Benzinga·11/04/2026 19:04:16
Listen to the news
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $617 to $626.